AIA Group Ltd Buys 1,088 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

AIA Group Ltd increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 6.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,764 shares of the medical research company's stock after purchasing an additional 1,088 shares during the period. AIA Group Ltd's holdings in Thermo Fisher Scientific were worth $9,762,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Norges Bank acquired a new position in Thermo Fisher Scientific during the fourth quarter worth about $3,149,754,000. Proficio Capital Partners LLC grew its stake in shares of Thermo Fisher Scientific by 68,617.0% in the 4th quarter. Proficio Capital Partners LLC now owns 762,759 shares of the medical research company's stock worth $396,810,000 after purchasing an additional 761,649 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $377,901,000. Lindsell Train Ltd bought a new stake in Thermo Fisher Scientific during the fourth quarter worth approximately $211,858,000. Finally, Charles Schwab Investment Management Inc. grew its position in Thermo Fisher Scientific by 15.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,810,128 shares of the medical research company's stock worth $1,461,913,000 after buying an additional 366,191 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Analyst Ratings Changes

TMO has been the subject of several research reports. Citigroup reduced their price objective on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Royal Bank of Canada set a $693.00 price target on Thermo Fisher Scientific in a research note on Friday, January 31st. Morgan Stanley upped their price objective on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an "overweight" rating in a research note on Friday, January 31st. Wells Fargo & Company boosted their price target on shares of Thermo Fisher Scientific from $660.00 to $680.00 and gave the company an "overweight" rating in a report on Friday, January 31st. Finally, Scotiabank raised their price objective on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the stock a "sector perform" rating in a research note on Monday, February 3rd. Four equities research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $653.23.

Remove Ads

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the completion of the sale, the chief executive officer now owns 115,174 shares in the company, valued at approximately $59,506,950.58. This trade represents a 7.99 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Michael A. Boxer sold 3,775 shares of the business's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the transaction, the senior vice president now owns 10,816 shares in the company, valued at $5,759,736.32. This represents a 25.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 23,900 shares of company stock valued at $13,106,062. 0.34% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Up 1.3 %

NYSE TMO traded up $6.28 during trading on Wednesday, hitting $489.25. 2,067,351 shares of the company traded hands, compared to its average volume of 1,625,339. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $184.57 billion, a P/E ratio of 29.60, a PEG ratio of 2.99 and a beta of 0.79. The business has a fifty day simple moving average of $538.56 and a 200 day simple moving average of $550.11. Thermo Fisher Scientific Inc. has a 12 month low of $473.50 and a 12 month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, topping analysts' consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, March 14th. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.35%. Thermo Fisher Scientific's payout ratio is 10.41%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.